Aldeyra Therapeutics (NASDAQ:ALDX) Stock Rating Upgraded by ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Aldeyra Therapeutics (NASDAQ:ALDX) from a hold rating to a buy rating in a research note published on Thursday, September 20th.

Other equities analysts have also recently issued research reports about the company. Cantor Fitzgerald reiterated a buy rating and set a $23.00 target price on shares of Aldeyra Therapeutics in a report on Tuesday, June 26th. Zacks Investment Research cut Aldeyra Therapeutics from a hold rating to a sell rating in a report on Tuesday, July 17th. Canaccord Genuity reiterated a buy rating and set a $27.00 target price on shares of Aldeyra Therapeutics in a report on Friday, August 10th. Finally, Janney Montgomery Scott started coverage on Aldeyra Therapeutics in a report on Thursday, September 13th. They set a buy rating for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of Buy and an average price target of $24.92.

Aldeyra Therapeutics stock traded up $0.64 during mid-day trading on Thursday, hitting $12.49. 853,643 shares of the company’s stock were exchanged, compared to its average volume of 280,891. The company has a market capitalization of $289.45 million, a PE ratio of -8.92 and a beta of 0.47. Aldeyra Therapeutics has a fifty-two week low of $5.55 and a fifty-two week high of $16.70. The company has a current ratio of 8.11, a quick ratio of 8.11 and a debt-to-equity ratio of 0.03.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.03). Analysts predict that Aldeyra Therapeutics will post -1.78 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its holdings in shares of Aldeyra Therapeutics by 19.8% in the 1st quarter. JPMorgan Chase & Co. now owns 59,502 shares of the biotechnology company’s stock valued at $446,000 after acquiring an additional 9,826 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Aldeyra Therapeutics by 22.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 62,429 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 11,506 shares during the last quarter. Northern Trust Corp lifted its stake in Aldeyra Therapeutics by 34.3% in the 1st quarter. Northern Trust Corp now owns 48,151 shares of the biotechnology company’s stock valued at $361,000 after purchasing an additional 12,290 shares during the last quarter. Rhumbline Advisers acquired a new stake in Aldeyra Therapeutics in the 2nd quarter valued at about $113,000. Finally, Element Capital Management LLC acquired a new stake in Aldeyra Therapeutics in the 1st quarter valued at about $123,000. Institutional investors own 57.83% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Read More: What are the benefits of buying treasury bonds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply